Anti-CD20 antibodies in relapsing multiple sclerosis: Protocol for a systematic 1 2 review and network meta-analysis 3 4 **Short title:** Anti-CD20 in multiple sclerosis: a network meta-analysis 5 6 Authors and affiliations 7 Cristian Eduardo Navarro 12\*, Simón Cárdenas-Robledo 34, Jaiver Macea 5, Natalia A 8 Ortíz-Cano 6, Ivan D Florez 789 9 10 <sup>1</sup> School of Medicine, Universidad de Antioquia. Medellín, Colombia 11 <sup>2</sup> Grupo de Investigación E.S.E Hospital Emiro Quintero Cañizares. Ocaña, Colombia 12 <sup>3</sup> Centro de Esclerosis Múltiple, Hospital Universitario Nacional (CEMHUN). Bogotá, 13 Colombia 14 <sup>4</sup> Departamento de Medicina Interna, Universidad Nacional de Colombia, Bogotá, 15 Colombia 16 <sup>5</sup> Research Group Experimental Neurology, Department of Neurosciences, KU Leuven. 17 Leuven, Belgium 18 <sup>6</sup> Pharmacy Department, Hospital Pablo Tobón, Medellín, Colombia 19 <sup>7</sup> Department of Pediatrics, University of Antioquia, Medellín, Colombia 20 <sup>8</sup> School of Rehabilitation Science, McMaster University. Hamilton, Canada 21 <sup>9</sup> Pediatric Intensive Care Unit, Clínica Las Americas-AUNA. Medellín, Colombia 22 23 \* Corresponding autor: 24 E-mail: cristian.navarro@udea.edu.co

# **Abstract**

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

**Background:** Multiple sclerosis is a chronic disease of the central nervous system characterized by autoimmune demyelination. Various immunomodulatory medications are available for its treatment, among which anti-CD20 monoclonal antibodies have demonstrated superior efficacy compared to other disease-modifying therapies. However, there is a lack of direct comparison between the four available anti-CD20 monoclonal antibodies. Therefore, this study aims to systematically assess the relative efficacy and safety of anti-CD20 monoclonal antibodies for treating relapsing multiple sclerosis. Materials and Methods: We will conduct a systematic review of phase IIb and phase III clinical trials of anti-CD20 monoclonal antibodies for the treatment of relapsing multiple sclerosis, following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A comprehensive review of the Cochrane Central Register of Controlled Trials; MEDLINE; Embase; ClinicalTrials; International Clinical Trials Registry Platform; OpenGray; and MedRxiv will be performed. Two independent reviewers will select titles, abstracts, and eligible full texts to execute the data extraction. The risk of bias will be assessed with the Cochrane RoB 2 tool. Data on prespecified outcomes will be analyzed for the selected articles using a random-effects network meta-analysis with a frequentist framework. Summary statistics, along with 95% confidence intervals will be presented, and the effectiveness and safety of each intervention will be ranked using the surface under the cumulative ranking curve. A missing data and a sensitivity analysis will be conducted. We will use the GRADE approach to assess the certainty of the direct, indirect, and network estimate for all outcomes.

- 49 Results and Conclusion: The results will provide evidence of the relative efficacy and
- 50 safety of anti-CD20 monoclonal antibodies for the treatment of relapsing multiple
- 51 sclerosis.
- Systematic review registration: PROSPERO registration number CRD42023437996 52

# Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects millions of people worldwide [1,2]. MS is characterized by the loss of myelin, which leads to impaired nerve function and disability. Demyelination was traditionally considered to be caused by autoreactive T lymphocytes [3], but the role of B lymphocytes in the MS pathogenesis has been increasingly recognized during the last two decades [4]. As a result, B cell depleting anti-CD20 monoclonal antibodies have emerged as promising disease-modifying therapies (DMTs) for MS [5–8]. Early phase 1 and phase 2 trials showed reduction in magnetic resonance imaging (MRI) activity (in the form of new/enlarging FLAIR/T2 lesions and gadolinium-enhancing [Gd+] lesions) and a discrete reduction in the long-term clinical outcome in people with inflammatory activity in MRI after treatment with rituximab [9,10]. Three new anti-CD20 monoclonal antibodies have been approved by regulatory agencies for the use in relapsing-remitting MS (ocrelizumab, ofatumumab and ublituximab), and primary progressive MS (ocrelizumab). All three have been studied in phase 3 randomized controlled trials (RCTs) [11–14]. These have had active comparator and placebo arms and have shown to be effective in reducing the disease relapsing rates. but, to our knowledge, no direct comparison between each other, or with rituximab has been published. As a result, to date it is not clear whether the anti-CD20 are similar in their beneficial effects and potential harms. Since head-to-head RCTs comparing the interventions among them may take years if not decades, the alternative is to conduct evidence synthesis methods that allow us to estimate the relative efficacy using indirect evidence in the cases when direct evidence is not available.

# **Materials and Methods**

77

100

cross-over trials will not be included.

**Study registration** 78 79 This protocol is reported in accordance to the Preferred Reporting Items for Meta-80 Analyses Protocols (PRISMA-P) guidelines (S1 Table) [15] and has been registered in 81 the International Prospective Register of Systematic Reviews (PROSPERO) 82 (registration number CRD42023437996). 83 **Objective** 84 85 Assess the comparative efficacy, safety, and tolerability of anti-CD20 monoclonal 86 antibodies for treating relapsing MS, through a systematic review and network meta-87 analysis (NMA). 88 Eligibility criteria 89 90 Type of studies and participants 91 We will include phase 2b and phase 3 placebo-controlled, and active-comparator RCTs. 92 Active comparators will include any other anti-CD20 monoclonal antibody or any other 93 DMT, such as, but not restricted to: alemtuzumab, cladribine, dimethyl fumarate, 94 fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b, pegylated 95 interferon beta-1a, natalizumab, ozanimod, siponimod, and teriflunomide. Patients 18 96 years of age and older with MS confirmed with 2010 or 2017 McDonald criteria 97 [16,17], and with a relapsing-remitting course according to the current classification 98 will be included [18]. Studies published in English or Spanish will be included, with no 99 restriction regarding the year of publication. Quasi-randomized, open-label, cluster and

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

**Type of interventions** The interventions to be assessed are anti-CD20 monoclonal antibodies (ocrelizumab. ofatumumab, rituximab, ublituximab) irrespective of dose, dosage form, route of administration, administration frequency, duration of treatment, and previous exposure to any active interventions. **Type of outcomes** Considering the prioritized outcomes suggested by the MS Core Outcome Set [19], the primary efficacy outcome will be the annualized relapse rate (ARR) defined as the number of confirmed relapses of multiple sclerosis per participant-year. The secondary efficacy outcomes will be the proportion of patients with disability progression confirmed at 12 week- and 24 week- (confirmed disability progression defined as an increase from the baseline EDSS [Expanded Disability Status Scale] score of at least 1.0 point or 0.5 points if the baseline EDSS score was >5.5) [20], and the number of Gd+ lesions and the new/enlarging FLAIR/T2 lesions. The primary safety outcome will be the proportion of patients with any adverse event (AE) as defined by the study authors. The proportion of patients with serious adverse events (SAE) and infusion-related reactions will be considered as secondary safety outcomes. **Information sources and search strategy** Data sources and search strategy We will search the following databases from their inception: Cochrane Central Register of Controlled Trials, MEDLINE, Embase, ClinicalTrials (https://clinicaltrials.gov),

126 International Clinical Trials Registry Platform (https://www.who.int/clinical-trials-127 registry-platform/the-ictrp-search-portal), OpenGrav (https://easy.dans.knaw.nl/ui/home), and MedRxiv (https://www.medrxiv.org). We will 128 129 also review the reference lists of included studies and relevant reviews for additional 130 studies not included after the main searches. 131 132 To build the search strategy a list of MeSH terms and keywords related to "anti-CD20", 133 "Antibodies, Monoclonal", "drug-modifying therapy", "multiple sclerosis", "Multiple 134 Sclerosis, Relapsing-Remitting", "ocrelizumab", "ofatumumab", "rituximab" and 135 "ublituximab" will be considered. We will use the validated RCT filter created by the 136 McMaster University Health Information Research Unit for MEDLINE and Embase 137 through the Ovid platform. These filter provide a good balance between sensitivity and 138 specificity [21]. 139 140 The preliminary and the final search strategy will be based on the recommendations 141 provided by the Cochrane Handbook for Systematic Reviews of Interventions [22], 142 tailored to be specific for each database. A draft of the MEDLINE search strategy is 143 shown in Table 1. We will export all the searches results to Mendeley® version 1.19.8 144 and will remove duplicates.

Table 1. Draft of search strategy in MEDLINE (via Ovid)

145

146

Search	Terms
1	exp Multiple Sclerosis/ or Multiple Sclerosis.mp. or (exp Multiple Sclerosis, Relapsing-Remitting/ or Multiple Sclerosis, Relapsing-Remitting.mp.)
2	(multiple sclerosis and (relapsing-remitting or relapsing remitting)).tw.

3	1 or 2
4	exp Antibodies, Monoclonal/ or Antibodies, Monoclonal.mp. or (exp Rituximab/ or Rituximab.mp.)
5	(monoclonal antibod* or antiCD20 or anti CD20 or anti-CD20 or rituximab or ocrelizumab or ofatumumab or ublituximab).tw.
6	4 or 5
7	3 and 6
8	randomized controlled trial.pt.
9	randomized.mp.
10	placebo.mp.
11	8 or 9 or 10
12	7 and 11

# Selection process, data collection and management

#### **Study selection**

147

148

149

150

151

152

153

154

155

156

157

158

159

Two independent reviewers (CEN, JM) will independently and in duplicate screen all he retrieved titles and abstracts to determine their eligibility according to a prespecified and piloted screening format. We will retrieve the full-text references of studies that at least one review author considers to be eligible during the screening. The full-text records will then be reviewed to determine the eligibility criteria using a prespecified and piloted screening format. Disagreements between the reviewers will be resolved by consensus. In the event of persistence of discrepancy between the two reviewers a third evaluator will determine the eligibility (IDF). We will report a PRISMA flow diagram of included and excluded articles [23]. The "Characteristics of excluded studies" section will detail the primary reason for exclusions.

**Data extraction** 

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

Two authors (CEN, JM) will extract data from the eligible studies using a standardized data extraction form independently and in duplicate. This will include 1) characteristics of the study: trial registry ID number, first author, year of publication, single or multicenter study, study design, inclusion/exclusion criteria, sample size per arm, recruitment and sampling procedures used, enrolment start and end dates, length of participant follow-up, methods used to prevent and control for confounding, source(s) of funding, authors' financial relationship and other potential conflicts of interest; 2) characteristics of participants; age in years, sex, time since symptom onset, disease duration, disability measured by EDSS, pre-intervention mean number of relapses, mean baseline number of FLAIR/T2 and Gd+ T1 lesions, previous DMT used; 3) details of the intervention and comparator: intervention, dose, formulation, frequency and mode of application, duration of administration; and 4) outcome results: outcome, timing of outcome measurements, number of participants randomly assigned and included in the analysis, number of participants who withdrew, were lost to follow-up or were excluded, number of any adverse event occurred, number of serious adverse events and number of infusion-related reactions. For dichotomous outcomes we will extract the number of events and number of participants randomized and for continuous outcomes, the mean and standard deviations (SD) per arm.

#### Risk of bias assessment

Two independent reviewers (CEN, JM) will assess the risk of bias in duplicate of the included studies using the Cochrane RoB 2 tool [24], which includes the following domains: bias arising from the randomization process, bias due to deviations from

intended interventions, bias due to missing outcome data, bias in the measurement of the outcome; and bias in the selection of the reported result. For each domain, we will reach a risk of bias judgment, assigning one of three levels to each domain: low risk of bias; some concerns; or high risk of bias. The overall risk of bias domain will be classified as: 'low risk of bias' when all domains are judged as low risk, 'some concerns' when at least one domain is some concern but was not high risk for any domain and 'high risk' if at least one domain was high risk or if multiple domains were judged as some concerns [24]. Any discrepancies will be resolved through discussion or by a third reviewer (IDF). Studies will not be excluded based on the risk of bias assessments, but we will conduct sensitivity analyses to explore the potential effects of high risk of bias in the meta-analyses. Industry funding will be considered as a potential source of bias [25].

# Data synthesis

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

We will summarize trial and population characteristics, using descriptive statistics. For each separate outcome, we will present a network plot of available trial data to be included in the analysis. Network nodes will represent interventions compared within trials and edges will represent trials directly comparing the corresponding interventions. We are primarily interested in the following nodes: rituximab, ocrelizumab, of a tumumab and ublituximab. We anticipate some degree of variability in the way in which the interventions are administered. Namely, some interventions may have been evaluated at different doses and regimens of administration. Therefore, if we identify heterogeneity at the pairwise comparisons levels and this seems to be related to differences in the doses or methods of administration, we will split some interventions into two or more nodes to represent these differences. The size of each node will be

proportional to the number of participants in the underlying intervention, and each line edges will be weighted according to the number of studies comparing the interventions it connects. To identify the most influential comparisons in the network, we will present the contribution matrix describing the contribution of each direct estimate to the entire network of trials [26].

#### Statistical analysis

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

We will conduct a network meta-analysis (NMA) using a frequentist framework. We will use a random-effects model to estimate the treatment effect for each drug compared to placebo and with other DMT [27,28]. We will also compare the efficacy and safety of each drug to each other using a network meta-analysis (NMA) using multivariate distributions to allow for the simultaneous analysis of multiple interventions and account for correlations induced by multi-arm trials [29]. We will calculate odds ratio (OR) for dichotomous outcomes and mean differences (MD) or standardized mean differences (SMD) for continuous outcomes, both with their corresponding 95% confidence intervals (95%CIs). If a study does not provide enough data for conducting the statistical analysis, we will try contacting the study authors. If this is not feasible, or we do not obtain any response from them, and the required data is crucial for the analysis (eg, mean results for continuous outcomes) we will exclude the study from the pooled data and present the information narratively. In case authors provide variability measures in a different format (eg, standard error, or 95%CI), we will follow the recommendations by the Cochrane Handbook of Systematic Reviews to estimate the required standard deviation [22]. When studies report median and ranges or interquartile ranges, we will use the methods by Wan to estimate the best mean and SD [30].

Pairwise meta-analysis

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

We will conduct pairwise meta-analysis of the available direct comparisons. We will conduct an inverse variance random-effects meta-analysis to estimate overall effect using OR for dichotomous data and MD or SMD for continuous outcomes. We will assess heterogeneity by visually comparing clinical and methodological characteristics of the included studies and by visual inspection of study effect sizes and their variation in the forest plots. We will also calculate the Chi square test for heterogeneity, and the I<sup>2</sup> statistic. We will consider an I<sup>2</sup> value >50% to be indicative of substantial heterogeneity [31]. We will perform subgroup or sensitivity analyses to explore the potential reasons behind substantial or considerable heterogeneity, namely, the potential effect modifiers. A priori, we have identified the following variables might be effect modifiers: age, relapses in the 12 months prior to randomization, disease severity according to EDSS, presence of GD+ lesions in MRI, and previous use of other DMT. We hypothesize that patients with younger age, high number of relapses at baseline, milder disability, the presence of Gd+ lesions and no prior treatment show larger effect. To assess the credibility of an apparent effect modification, we will use the Instrument for assessing the Credibility of Effect Modification Analyses (ICEMAN) [32].

# Network meta-analysis

We will conduct an inverse variance random-effects meta-analysis to estimate overall effect sizes, that is respectively ORs or MDs/SMDs for dichotomous or continuous outcomes, along with their corresponding 95%CIs, under the assumption that different trials are estimating different but related true effects. We will use the Hartung-Knapp-Sidik-Jonkman method to calculate a 95%CI for the overall effect size to handle meta-

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

analyses with a small number of studies [33]. We will rank the drugs according to their efficacy and safety based on P-scores. For a connected network of trials, we will conduct a random-effects NMA [34], if we consider that the assumptions of transitivity and consistency are justifiable. For transitivity, we are assuming that participants are equally likely to be randomized to any of the included interventions and that trials are sufficiently similar across comparisons with respect to their effect modifiers distribution. We will consider the same effect modifiers described above as potential causes of heterogeneity. To explore variability in intervention definitions, we will split them into separate nodes according to the doses administered in the included trials. The statistical manifestation of intransitivity can create inconsistency between direct and indirect evidence. We will assess consistency within each network using both global and local statistical approaches. We will evaluate each network using the designby-treatment interaction test, and accounting for multiple sources of inconsistency due to disagreements in trials with different designs [35–37]. We will also evaluate consistency in each loop of interventions in each network using the loop-specific approach, and between each direct and indirect evidence using the node-splitting approach [38,39]. We will plot all consistency estimates and their 95%CIs to make inferences about the presence of inconsistency locally in the network. Missing data and sensitivity analysis We will conduct sensitivity analyses to assess the robustness of our findings for the primary outcomes. First, we will conduct an analysis by excluding studies with an

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

overall high risk of bias. If the results are very different from the analyses including all studies, we will prioritize the results obtained from the studies with 'low risk' and 'some concerns' analyses for our primary findings. Second, we will perform an analysis excluding trials for which we imputed data. Lastly, we will perform an analysis using the intention to treat denominators, in the case of trials that had data imputed. In case of missing participant data, we will capture the type of data imputation used by the trial authors in our extraction form, to assess the appropriateness of the data imputation method. For missing outcome data, we will try to contact authors for more information. If the trial authors do not respond, we will consider alternatives such as imputation approaches. If the missing data from the studies are significant, we will consider this in the 'Bias due to missing outcome data' criterion of the RoB 2 assessment. We will use comparison-adjusted funnel plots to assess the likelihood of reporting bias and small-study effects for the NMA when at least 10 studies per outcome are available [40–42]. In the case of funnel plot asymmetry, we will explore possible sources of it, including poor methodological quality in smaller trials, true heterogeneity, nonreporting biases, and baseline risk differences. In the cases in which the key assumptions are not met (transitivity and consistency), we will provide only pairwise estimates and a narrative description of the results. We will use R software version 4.3.2 (The R Foundation, Wien, Austria) for the analyses. Summary of findings and assessment of the certainty of the evidence

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

We will use the GRADE approach to assess the certainty of the direct, indirect, and network estimate for all outcomes. Two review authors (CEN, JM) will independently assess the certainty of the evidence for each outcome. Where necessary, we will resolve any disagreements between authors through discussion or by consultation with a third review author (IDF). For the direct evidence, the assessment starts by considering evidence from RCTs to be of high certainty, and the body of summarized evidence is assessed against five criteria: study limitations (risk of bias) [43], inconsistency [44], indirectness [45] imprecision [46], and publication bias [47]. For the "study limitations" criterion, we will use the overall risk of bias assessment judgment obtained from the RoB 2 tool [24]. For the specific NMA GRADE assessment we will use the specific approach that considers intransitivity [48] and incoherence criteria [49] and we will apply the approach to draw conclusions from the NMA sing a minimally-contextualized framework [50]. **Ethical consideration** This study does not require ethical approval as it is a secondary analysis of published data. We will disseminate the results of this study through publication in a peerreviewed journal and presentation at relevant conferences.

# **Discussion and conclusion**

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

This protocol outlines a network meta-analysis comparing the efficacy and safety of anti-CD20 monoclonal antibodies for treating relapsing multiple sclerosis. Anti-CD20 monoclonal antibodies have shown remarkable results in terms of efficacy for treating MS, which has led to their inclusion in an application to the World Health Organization essential medicines list [51]. However, their relative efficacy between them has not been assessed in controlled trials to date. Several RCTs aiming to demonstrate the non-inferiority of rituximab in comparison to ocrelizumab are underway [52–55], but results are expected for 2025 at the earliest. Further, to the best of our knowledge there are no studies underway comparing the efficacy of the newer anti-CD20 monoclonal antibodies. Therefore, the results of this study will provide valuable information to guide clinical decision-making, to inform future research in this area, and to develop new health economic evaluations related to these DMTs [56]. We expect difficulties for the completion of this study, for we anticipate that we will find a limited number of RCTs, with high heterogeneity which probably will affect the results of the meta-analysis.

# References

346

347 1. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple 348 sclerosis. Nat Rev Dis Prim. 2018;4: 43. doi:10.1038/s41572-018-0041-4 349 2. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising 350 prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third 351 edition. Mult Scler J. 2020;26: 1816–1821. doi:10.1177/1352458520970841 352 3. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - The plaque and its 353 pathogenesis. N Engl J Med. 2006;354: 942–955. doi:10.1056/NEJMra052130 354 von Büdingen H-C. Palanichamy A. Lehmann-Horn K. Michel BA. Zamvil SS. 4. 355 Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-356 drivers and therapeutic targets. Eur Neurol. 2015;73: 238–246. 357 doi:10.1159/000377675 358 5. Xu X, Chi S, Wang Q, Li C, Xu B, Zhang J, et al. Efficacy and safety of 359 monoclonal antibody therapies for relapsing remitting multiple sclerosis: A 360 network meta-analysis. Mult Scler Relat Disord. 2018;25: 322–328. 361 doi:10.1016/j.msard.2018.08.026 362 Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple 6. 363 sclerosis. Cochrane Database Syst Rev. 2021;11: CD013874. 364 doi:10.1002/14651858.CD013874.pub2 7. 365 Huygens S, Versteegh M. Modeling the cost-utility of treatment sequences for 366 multiple sclerosis. Value Heal. 2021;24: 1612–1619. 367 doi:10.1016/j.jval.2021.05.020 368 8. Chen C, Zhang E, Zhu C, Wei R, Ma L, Dong X, et al. Comparative efficacy and 369 safety of disease-modifying therapies in patients with relapsing multiple 370 sclerosis: A systematic review and network meta-analysis. J Am Pharm Assoc.

- 371 2023;63: 8-22.e23. doi:10.1016/j.japh.2022.07.009
- 372 9. Bar-Or A, Calabresi PAJ, Arnlod D, Markowitz C, Shafer S, Kasper LH, et al.
- Rituximab in relapsing-remitting multiple sclerosis. Ann Neurol. 2008;63: 395–
- 374 400. doi:10.1002/ana.21363
- 375 10. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell
- depletion with rituximab in relapsing—remitting multiple sclerosis. N Engl J Med.
- 377 2008;358: 676–688. doi:10.1056/nejmoa0706383
- 378 11. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al.
- Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J
- 380 Med. 2017;376: 209–220. doi:10.1056/NEJMoa1606468
- 381 12. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al.
- Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J
- 383 Med. 2017;376: 221–234. doi:10.1056/nejmoa1601277
- 384 13. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al.
- Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:
- 386 546–557. doi:10.1056/nejmoa1917246
- 387 14. Steinman L, Fox E, Hartung H-P, Alvarez E, Qian P, Wray S, et al. Ublituximab
- versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387:
- 389 704–714. doi:10.1056/NEJMoa2201904
- 390 15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
- Preferred reporting items for systematic review and meta-analysis protocols
- 392 (PRISMA-P) 2015 statement. Syst Rev. 2015;4: 1–9. doi:10.1186/2046-4053-4-1
- 393 16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald
- 395 criteria. Ann Neurol. 2011;69: 292–302. doi:10.1002/ana.22366

396 17. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. 397 Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet 398 Neurol. 2018;17: 162–173. doi:10.1016/S1474-4422(17)30470-2 399 18. Lublin FD, Reingold SC, Cohen JA, Cutter GR, S??rensen PS, Thompson AJ, et 400 al. Defining the clinical course of multiple sclerosis: The 2013 revisions. 401 Neurology. 2014:83: 278–286. doi:10.1212/WNL.000000000000560 402 19. Daniels K, Frequin STFM, van de Garde EMW, Biesma DH, van der Wees PJ, 403 van der Nat PB, et al. Development of an international, multidisciplinary, patient-404 centered Standard Outcome Set for Multiple Sclerosis: The S.O.S.MS project. 405 Mult Scler Relat Disord. 2023;69: 104461. doi:10.1016/j.msard.2022.104461 406 20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded 407 disability status scale (EDSS). Neurology. 1983;33: 1444–1444. 408 doi:10.1212/WNL.33.11.1444 409 21. Health Information Research Unit (HIRU). Search filters for MEDLINE in Ovid 410 syntax and the PubMed translation. 2023. Available: 411 https://hiruweb.mcmaster.ca/hkr/hedges/medline/ 412 22. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane 413 Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester, UK: 414 John Wiley & Sons; 2019. 415 23. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. 416 The PRISMA extension statement for reporting of systematic reviews 417 incorporating network meta-analyses of health care interventions: Checklist and 418 explanations. Ann Intern Med. 2015;162: 777–784. doi:10.7326/M14-2385 419 Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 24.

420

2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019: 14898.

- 421 doi:10.1136/bmj.14898
- 422 25. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and
- 423 research outcome. Cochrane Database Syst Rev. 2012; MR000033.
- 424 doi:10.1002/14651858.MR000033.pub2
- 425 Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Giovane C 26.
- 426 Del. Egger M. et al. Assessing confidence in the results of network meta-analysis
- 427 (Cinema). bioRxiv. 2019; 597047. doi:10.1101/597047
- 428 27. Rücker G. Network meta-analysis, electrical networks and graph theory. Res
- 429 Synth Methods. 2012;3: 312–324. doi:10.1002/jrsm.1058
- 430 28. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis
- 431 works without resampling methods. BMC Med Res Methodol. 2015;15: 58.
- 432 doi:10.1186/s12874-015-0060-8
- 433 29. Rücker G, Cates CJ, Schwarzer G. Methods for including information from
- 434 multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017;8: 392–403.
- 435 doi:10.1002/jrsm.1259
- 436 30. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
- 437 deviation from the sample size, median, range and/or interquartile range. BMC
- 438 Med Res Methodol. 2014;14: 135. doi:10.1186/1471-2288-14-135
- 439 31. Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327: 557–
- 440 560. doi:10.1136/bmj.327.7414.557
- 441 32. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward
- 442 RA, et al. Development of the Instrument to assess the Credibility of Effect
- 443 Modification Analyses (ICEMAN) in randomized controlled trials and meta-
- 444 analyses. Can Med Assoc J. 2020;192: E901–E906. doi:10.1503/cmaj.200077
- 445 Veroniki AA, Jackson D, Bender R, Kuss O, Langan D, Higgins JPT, et al. 33.

446 Methods to calculate uncertainty in the estimated overall effect size from a 447 random-effects meta-analysis. Res Synth Methods. 2019;10: 23–43. 448 doi:10.1002/jrsm.1319 449 Salanti G. Indirect and mixed-treatment comparison, network, or multiple-34. 450 treatments meta-analysis: many names, many benefits, many concerns for the 451 next generation evidence synthesis tool. Res Synth Methods. 2012;3: 80–97. 452 doi:10.1002/jrsm.1037 453 Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and 35. 454 inconsistency in network meta-analysis: concepts and models for multi-arm 455 studies. Res Synth Methods. 2012;3: 98-110. doi:10.1002/jrsm.1044 456 36. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in 457 network meta-analysis: model estimation using multivariate meta-regression. Res 458 Synth Methods. 2012;3: 111–125. doi:10.1002/jrsm.1045 459 37. Krahn U, Binder H, König J. A graphical tool for locating inconsistency in 460 network meta-analyses. BMC Med Res Methodol. 2013;13: 35. 461 doi:10.1186/1471-2288-13-35 462 38. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed 463 treatment comparison meta-analysis. Stat Med. 2010;29: 932–944. 464 doi:10.1002/sim.3767 465 39. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency 466 in networks of interventions. Int J Epidemiol. 2013;42: 332–345. 467 doi:10.1093/ije/dys222 468 40. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a 469 simple, graphical test. BMJ. 1997;315: 629–634. doi:10.1136/bmj.315.7109.629 470 41. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of

- 471 small-study effects in a network of interventions. Res Synth Methods. 2012;3:
- 472 161-176. doi:10.1002/jrsm.57
- 473 42. Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools
- 474 for network meta-analysis in STATA. PLoS One. 2013;8: e76654.
- 475 doi:10.1371/journal.pone.0076654
- 476 Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. 43.
- 477 GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of
- 478 bias). J Clin Epidemiol. 2011;64: 407–415. doi:10.1016/j.jclinepi.2010.07.017
- 479 44. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.
- 480 GRADE guidelines: 7. Rating the quality of evidence - inconsistency. J Clin
- 481 Epidemiol. 2011;64: 1294–1302. doi:10.1016/j.jclinepi.2011.03.017
- 482 Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. 45.
- 483 GRADE guidelines: 8. Rating the quality of evidence - indirectness. J Clin
- 484 Epidemiol. 2011;64: 1303–1310. doi:10.1016/j.jclinepi.2011.04.014
- 485 46. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.
- 486 GRADE guidelines 6. Rating the quality of evidence - imprecision. J Clin
- 487 Epidemiol. 2011;64: 1283–1293. doi:10.1016/j.jclinepi.2011.01.012
- 488 47. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE
- 489 guidelines: 5. Rating the quality of evidence - publication bias. J Clin Epidemiol.
- 2011;64: 1277-1282. doi:10.1016/j.jclinepi.2011.01.011 490
- 491 48. Brignardello-Petersen R, Tomlinson G, Florez I, Rind DM, Chu D, Morgan R, et
- 492 al. Grading of recommendations assessment, development, and evaluation
- 493 concept article 5: addressing intransitivity in a network meta-analysis. J Clin
- 494 Epidemiol. 2023;160: 151–159. doi:10.1016/j.jclinepi.2023.06.010
- 495 49. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa

496		TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in
497		estimates from a network meta-analysis. J Clin Epidemiol. 2018;93: 36–44.
498		doi:10.1016/j.jclinepi.2017.10.005
499	50.	Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G,
500		Alhazanni W, et al. GRADE approach to drawing conclusions from a network
501		meta-analysis using a minimally contextualised framework. BMJ. 2020; m3900.
502		doi:10.1136/bmj.m3900
503	51.	The Lancet Neurology. Towards equitable access to treatment for multiple
504		sclerosis. Lancet Neurol. 2023;22: 189. doi:10.1016/S1474-4422(23)00041-8
505	52.	Torkildsen Ø, Myhr K-M. Ocrelizumab versus rituximab off-label at the onset of
506		relapsing MS disease (OVERLORD-MS). 2020. Available:
507		https://clinicaltrials.gov/study/NCT04578639
508	53.	Christensen JR, Sellebjerg F. Non-inferiority study of ocrelizumab and rituximab
509		in active multiple sclerosis (DanNORMS). 2020. Available:
510		https://clinicaltrials.gov/study/NCT04688788
511	54.	Michel L, Gazzola A. RItuximab versus ocrelizumab in relapsing-remitting
512		multiple sclerosis (TRIO). 2023. Available:
513		https://clinicaltrials.gov/study/NCT05758831
514	55.	Schoof L, Strijbis E. Non-inferiority study of rituximab compared to ocrelizumab
515		in relapsing MS (Noisy Rebels). 2023. Available:
516		https://clinicaltrials.gov/study/NCT05834855
517	56.	Navarro CE, Betancur JE. Cost-utility analysis comparing ocrelizumab vs
518		rituximab in the treatment of relapsing-remitting multiple sclerosis: The
519		Colombian perspective. Value Heal Reg Issues. 2023;36: 83–91.
520		doi:10.1016/j.vhri.2023.02.008

# **Supporting information**

- S1 Table. PRISMA-P (Preferred Reporting Items for Systematic review and Meta-522
- Analysis Protocols) 2015 checklist 523

521